title: Inclusion body myositis: explanation for poor response to immunosuppressive therapy.
abstract: We treated eight patients who had inclusion body myositis (IBM) with oral prednisone therapy, and we performed muscle biopsies before and after treatment. We documented the patients' clinical response to therapy and changes in serum CK. Although the serum CK level fell, muscle strength worsened after prednisone treatment. In addition, while inflammation decreased in the muscle biopsy specimens, the number of vacuolated and amyloid-positive fibers increased after oral prednisone therapy. These observations indicate that the inflammatory response in IBM may play a secondary role in the pathogenesis of IBM. The unique findings of intracellular amyloid deposits and rimmed vacuoles distinguishing IBM from other inflammatory myopathies, and recognition that suppression of inflammation has no effect on the clinical course, suggest that IBM may represent a degenerative muscle disorder.
authors.affiliation: Department of Neurology, University of Texas Southwestern Medical Center, Dallas 75235-8897, USA.
authors.forename: R J
authors.initials: RJ
authors.lastname: Barohn
authors.forename: A A
authors.initials: AA
authors.lastname: Amato
authors.forename: Z
authors.initials: Z
authors.lastname: Sahenk
authors.forename: J T
authors.initials: JT
authors.lastname: Kissel
authors.forename: J R
authors.initials: JR
authors.lastname: Mendell
mesh_terms: D000368:Aged; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D002479:Inclusion Bodies / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000473:pathology; D009220:Myositis / Q000097:blood / Q000473:pathology / Q000628:therapy*
chemical_list: D007166:Immunosuppressive Agents; D003402:Creatine Kinase